Diabetes Mellitus: a Clinical Condition Associated with Metabolic Syndrome and Colorectal Cancer Risk
| Autor: | Vesna Brzački, Manolis S. Kallistratos, Athanasios J. Manolis, Aleksandar Nagorni, Dragan Lovic |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Pharmacology Oncology medicine.medical_specialty business.industry Colorectal cancer Cancer Type 2 Diabetes Mellitus Disease medicine.disease Biochemistry Obesity 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Insulin resistance 030220 oncology & carcinogenesis Diabetes mellitus Internal medicine Drug Discovery Genetics medicine Metabolic syndrome business |
| Zdroj: | Current Pharmacology Reports. 5:205-209 |
| ISSN: | 2198-641X |
| DOI: | 10.1007/s40495-019-00183-8 |
| Popis: | Colorectal cancer (CRC) is the third most commonly diagnosed carcinoma and the fourth leading cause of carcinoma deaths worldwide. Most cases of CRC occur in people aged over 50 years, often coexisting with other chronic diseases including obesity, type 2 diabetes mellitus, and cardiovascular disease. Diabetes mellitus (DM) and cancer frequently coexist. DM is associated with an increased risk for pancreatic, gastric, liver, colorectal, breast, urinary tract, and female reproductive cancers. It is hypothesized that possible biologic links between diabetes and cancer risk could be related to hormonal (insulin resistance), inflammatory, or metabolic (hyperglycemia) characteristics of DM, as well as with some antidiabetic medications. This review summarizes the current published literature regarding the association of CRC with diabetes since there is growing evidence from recent studies that this association is not random. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink